Topical Wound Care Treatment and Indications for Their Use

  • John C. LantisIIEmail author
  • Juan A. Paredes
Part of the Contemporary Diabetes book series (CDI)


In this chapter, we will explore the role of various topical wound care strategies, and the evidence, or lack thereof, in support of their use in diabetic foot ulcer patients. The chapter is divided into two major sections that cover Basic and Advanced wound care strategies. The myriad wound care compounds, dressings, and devices are discussed. The chapter concludes with general recommendation for ulcer management based on stage.


Diabetic foot ulcer (DFU) Growth factor therapy Topical therapy for DFU The goal of therapy for DFU Epithelialization Wound closure Recombinant Platelet Derived Growth Factor Dermal regeneration Permissive maintenance debridement 


  1. 1.
    Schultz GS, Sibbald RG, Falanga V, et al. Wound bed preparation: a systematic approach to wound management. Wound Repair Regen. 2003;11(Suppl 1):1–28.CrossRefGoogle Scholar
  2. 2.
    Wu L, Norman G, Dumville JC, O’Meara S, Bell-Syer SEM. Dressings for treating foot ulcers in people with diabetes: an overview of systematic reviews. Cochrane Database Syst Rev. 2015;7:CD010471. Scholar
  3. 3.
    Sood A, Granick MS, Tomaselli NL. Wound dressings and comparative effectiveness data. Adv Wound Care. 2014;3(8):511–29. Scholar
  4. 4.
    Eaglstein WH, Mertz PM, Falanga V. Occlusive dressings. Am Fam Phys. 1987;35:211–6.Google Scholar
  5. 5.
    Burton CS. Management of chronic and problem lower extremity wounds. Dermatol Clin. 1993;11:767–73.PubMedCrossRefGoogle Scholar
  6. 6.
    Varghese MC, Balin AK, Carter M, et al. Local environment of chronic wounds under synthetic dressings. Arch Dermatol. 1986;122:52–7.PubMedCrossRefGoogle Scholar
  7. 7.
    Motta G. Wound Source; The Kestrel wound product sourcebook. 8th ed. Toronto: Kestrel Health Information Inc; 2005. Google Scholar
  8. 8.
    Gilje O. On taping (adhesive tape treatment) of leg ulcers. Acta Dermatol Venereol. 1948;28:454–67.Google Scholar
  9. 9.
    Winter GD. Formation of the scab and the rate of epithelialization of superficial wounds in the skin of the young domestic pig. Nature (London). 1962;193:293–4.CrossRefGoogle Scholar
  10. 10.
    Hinman CD, Maibach H. Effect of air exposure and occlusion on experimental human skin wounds. Nature (London). 1963;200:377–9.CrossRefGoogle Scholar
  11. 11.
    Alvarez OM, Rozint J, Wiseman D. Moist environment for healing: matching the dressing to the wound. Wounds. 1989;1(1):35–50.Google Scholar
  12. 12.
    Hutchinson JJ, McGuckin M. Influence of occlusive dressings: a microbiological and clinical review. Am J Infect Control. 1990;18:257–68.PubMedCrossRefPubMedCentralGoogle Scholar
  13. 13.
    Choucair M, Phillips TJ. Wound dressings. In: Freedberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, Katz SI, Fitzpatrick TB, editors. Fitzpatrick’s dermatology in general medicine. 5th ed. New York: McGraw-Hill Book Co; 2000. p. 2954–8.Google Scholar
  14. 14.
    Darkovich SL, Brown-Etris M, Spencer M. Biofilm hydrogel dressing: a clinical evaluation in the treatment of pressure sores. Ostomy Wound Manage. 1990;29:47.PubMedPubMedCentralGoogle Scholar
  15. 15.
    Kucan JO, Robson MC, Heggers JP, et al. Comparison of silver sulfadiazine, povidone iodine and physiologic saline in the treatment of pressure ulcers. J Am Geriatr Soc. 1981;29:232–5.PubMedCrossRefPubMedCentralGoogle Scholar
  16. 16.
    Klasen HJ. A historical review of the use of silver in the treatment of burns. II. Renewed interest for silver. Burns. 2000;26:131–8.PubMedCrossRefPubMedCentralGoogle Scholar
  17. 17.
    Alvarez OM, Patel M, Booker J, Markowitz L. Effectiveness of a biocellulose wound dressing for the treatment of chronic venous leg ulcers: results of a single center randomized study involving 24 patients. Wounds. 2004;16(7):224–33.Google Scholar
  18. 18.
    Ovington LG. The well dressed wound: an overview of dressing types. Wounds. 1998;10(Suppl A):1A–11A.Google Scholar
  19. 19.
    Piaggesi A, Baccetti F, Rizzo L. Sodium carboxymethylcellulose dressings in the management of deep ulcerations of the diabetic foot. Diabet Med. 2001;18(4):320–4.PubMedCrossRefPubMedCentralGoogle Scholar
  20. 20.
    Gentzkow GD, Iwasaki SD, Hershon KS, Mengel M, Pendergast JJ, et al. Use of dermagraft a cultured human dermis, to treat diabetic foot ulcers. Diabetes Care. 1992;19:350–4.CrossRefGoogle Scholar
  21. 21.
    Kaya AZ, Turani N, Akyuz M. The effectiveness of a hydrogel dressing compared with standard management of pressure ulcers. J Wound Care. 2005;14:42.PubMedCrossRefGoogle Scholar
  22. 22.
    Anderson KE, Franken CPM, Gad P, Larsen AM, Larsen JR, van Neer PAFA, Vuerstaek J, Wuite J, Neumann HAM. A randomized, controlled study to compare the effectiveness of two foam dressings in the management of lower leg ulcers. Ostomy Wound Manage. 2002;48:34.Google Scholar
  23. 23.
    Alvarez OM, Mertz PM, Eaglstein WH. The effect of occlusive dressings on collagen synthesis and re-epithelialization in superficial wounds. J Surg Res. 1983;35:142–8.PubMedCrossRefGoogle Scholar
  24. 24.
    Alvarez OM, Hefton JM, Eaglstein WE. Healing wound: occlusion or exposure. Infect Surg. 1984;3:173–81.Google Scholar
  25. 25.
    Mustoe TA, O’Shaughnessy K, Kloeters O. Chronic wound pathogenesis and current treatment strategies: a unifying hypothesis. Plast Reconstr Surg. 2006;117:35S.PubMedCrossRefGoogle Scholar
  26. 26.
    Thomas S. Alginate dressings in surgery and wound management-part 3. J Wound Care. 2000;9:163–6.PubMedCrossRefGoogle Scholar
  27. 27.
    Ong S, Wu J, Moochhala SM, et al. Development of a chitosan-based wound dressing with improved hemostatic and antimicrobial properties. Biomaterials. 2008;29(32):4323–32.PubMedCrossRefGoogle Scholar
  28. 28.
    Storm-Versloot MN, Vos CG, Ubbink DT, Vermeulen H. Topical silver for preventing wound infection. Cochrane Database Syst Rev. 2010;3:CD006478. Scholar
  29. 29.
    Bergin S, Wraight P. Silver based wound dressings and topical agents for treating diabetic foot ulcers. Cochrane Database Syst Rev. 2006;1:CD005082. Scholar
  30. 30.
    Holloway GA, Johansen KH, Barnes RW, Pierce GE. Multicenter trial of cadexomer iodine to treat venous stasis ulcers. West J Med. 1989;151:35–8.PubMedPubMedCentralGoogle Scholar
  31. 31.
    Apelqvist J, Ragnarson Tennvall G. Cavity foot ulcers in diabetic patients: a comparative study of cadexomer iodine and standard treatment. An economic analysis alongside a clinical trial. Acta Dermatol Venereol. 1996;76:231–5.Google Scholar
  32. 32.
    Conklin A. UW study tests topical honey as a treatment for diabetic ulcers. Accessed 15 July 2011.
  33. 33.
    Shukrimi A, Sulaiman AR, Halim AY, et al. A comparative study between honey and povidone iodine as a dressing solution for Wagner type II diabetic foot ulcers. Med J Malaysia. 2008;63(1):44–6.PubMedGoogle Scholar
  34. 34.
    Jull AB, Rodgers A, Walker N. Honey as a topical treatment for acute and chronic wounds. Cochrane Database Syst Rev. 2008;4:CD005083. Scholar
  35. 35.
    Steed DL. Diabetic Ulcer Study Group: clinical evaluation of recombinant human platelet- derived growth factor for the treatment of lower extremity diabetic ulcers. J Vasc Surg. 1995;21:71–81.PubMedCrossRefGoogle Scholar
  36. 36.
    Ovington LG. Hanging wet to dry dressings out to dry. Home Healthc Nurse. 2001;19:477.PubMedCrossRefGoogle Scholar
  37. 37.
    Hutchinson JJ. Prevalence of wound infection under occlusive dressings: a collective survey of reported research. Wounds. 1989;1:123.Google Scholar
  38. 38.
    Lawrence JC. Dressings and wound infection. Am J Surg. 1994;167(Suppl 1A):1S.Google Scholar
  39. 39.
    Seaman S. Dressing selection in chronic wound management. J Am Podiatr Med Assoc. 2002;92:24.PubMedCrossRefGoogle Scholar
  40. 40.
    Castronuovo JJ Jr, Ghobrial I, Giusti AM, Rudolph S, Smiell JM. Effects of chronic wound fluid on the structure and biological activity of becaplermin (rhPDGF-BB) and becaplermin gel. Am J Surg. 1998;176:61S–7S.PubMedCrossRefGoogle Scholar
  41. 41.
    Smiell JM. Clinical safety of becaplermin (rhPDGF-BB) gel. Becaplermin Studies Group. Am J Surg. 1998;176:68S–73S.PubMedCrossRefGoogle Scholar
  42. 42.
    Steed DL, Donohoe D, Webster MW, Lindsley L. Effect of extensive debridement and treatment on the healing of diabetic foot ulcers. Diabetic Ulcer Study Group. J Am Coll Surg. 1996;183:61–4.PubMedGoogle Scholar
  43. 43.
    Steed DL, et al. Effect of extensive debridement and treatment on the healing of diabetic foot ulcers. J Am Coll Surg. 1996;183:61–4.PubMedGoogle Scholar
  44. 44.
    Martí-Carvajal AJ, Gluud C, Nicola S, Simancas-Racines D, et al. Growth factors for treating diabetic foot ulcers. Cochrane Database Syst Rev. 2015;10:CD008548. Scholar
  45. 45.
    Mulder G, Tallis AJ, Marshall VT, Mozingo D, Phillips L, Pierce GF, Chandler LA, Sosnowski BK. Treatment of nonhealing diabetic foot ulcers with a platelet-derived growth factor gene-activated matrix (GAM501): results of a phase 1/2 trial. Wound Repair Regen. 2009;17(6):772–9. Epub 2009 Oct 12CrossRefPubMedGoogle Scholar
  46. 46.
    Robson M, Phillips L. Platelet-derived growth factor BB for the treatment of chronic pressure ulcers. Lancet. 1992;339:23–5.PubMedCrossRefGoogle Scholar
  47. 47.
    Mustoe T, Cutler N. A phase II study to evaluate recombinant platelet-derived growth factor-BB in the treatment of stage 3 and 4 pressure ulcers. Arch Surg. 1994;129:212–9.CrossRefGoogle Scholar
  48. 48.
    Lantis J, Boone D, Gendics C, Todd G. Analysis of patient cost for recombinant human platelet-derived growth factor therapy as the first-line treatment of the insured patient with a diabetic foot ulcer. Adv Skin Wound Care. 2009;22(4):167–71.Google Scholar
  49. 49.
    Wieman T, Smiell J, Su Y. Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. Diabetes Care. 1998;21(5):822–7.PubMedCrossRefGoogle Scholar
  50. 50.
    U.S. Food and Drug Administration. FDA announces new labeling changes for Regranex: Product to carry boxed warning. FDA News Release. 2008. Accessed 16 July 2011.
  51. 51.
    Motley TA, Lange DL, Dickerson JE, Slade HB. Clinical outcomes associated with serial sharp debridement of diabetic foot ulcers with and without clostridial collagenase ointment. Wounds. 2014;26(3):57–64.PubMedGoogle Scholar
  52. 52.
    Gordon I, Lantis JC. Collagenase Diabetic Foot Ulcer Study Group. Clostridial Collagenase for the Management of Diabetic Foot Ulcers: results of four randomized controlled trials. NCT01143714; NCT01143727; NCT01408277; NCT01056198,
  53. 53.
    Pavan R, Jain S, Shraddha KA. Properties and therapeutic application of bromelain: a review. Biotechnol Res Int. 2012;2012:976203.PubMedPubMedCentralCrossRefGoogle Scholar
  54. 54.
    Demidova-Rice TN, Hamblin MR, Herman IM. Acute and impaired wound healing: pathophysiology and current methods for drug delivery, part 1: normal and chronic wounds: biology, causes, and approaches to care. Adv Skin Wound Care. 2012;25(7):304–14.PubMedPubMedCentralCrossRefGoogle Scholar
  55. 55.
    Feasibility study: enzymatic debridement in patients with partial thickness burns. Bethesda, MD: MediWound Ltd. National Library of Medicine (US); 2011. /NCT00898521.
  56. 56.
    Rosenberg L, Lapid O, Bogdanov-Berezovsky A. Safety and efficacy of a proteolytic enzyme for enzymatic burn debridement: a preliminary report. Burns. 2004;30(8):843–50.PubMedCrossRefGoogle Scholar
  57. 57.
    Ruoslahti E, Yamaguchi Y. Proteoglycans as modulators of growth factor activities. Cell. 1991;64(5):867–9.PubMedCrossRefGoogle Scholar
  58. 58.
    Kainulainen V, Wang H, Schick C, Bernfield M. Syndecans, heparan sulfate proteoglycans, maintain the proteolytic balance of acute wound fluids. J Biol Chem. 1998;273(19):11563–9.PubMedCrossRefGoogle Scholar
  59. 59.
    Ulrich D, Smeets R, Unglaub F, Woltje M, Pallua N. Effect of oxidized regenerated cellulose/collagen matrix on proteases in wound exudate of patients with diabetic foot ulcers. J Wound Ostomy Continence Nurs. 2011;38(5):522–8.PubMedCrossRefGoogle Scholar
  60. 60.
    Cullen B, Ivins N. Promogran & Promogran Prisma made easy. Wounds Int. 2010;1(3):1–6.Google Scholar
  61. 61.
    Serena TE. Development of a novel technique to collect proteases from chronic wounds. Adv Wound Care (New Rochelle). 2014;3(12):729–32.CrossRefGoogle Scholar
  62. 62.
    Manizate F, Fuller A, Gendics C, Lantis JC. A prospective, single-center, nonblinded, comparative, postmarket clinical evaluation of a bovine-derived collagen with ionic silver dressing versus a carboxymethylcellulose and ionic silver dressing for the reduction of bioburden in variable-etiology, bilateral lower-extremity wounds. Adv Skin Wound Care. 2012;25(5):220–5. Scholar
  63. 63.
    Veves A, Falanga V, Armstrong D, Sabolinski ML. Graftskin, a human skin equivalent, is effective in the management of noninfected neuropathic diabetic foot ulcers. Diabetes Care. 2001;24:290–3.PubMedCrossRefPubMedCentralGoogle Scholar
  64. 64.
    Martinson M, Martinson N. A comparative analysis of skin substitutes used in the management of diabetic foot ulcers. J Wound Care. 2016;25(Suppl 10):S8–S17.PubMedCrossRefGoogle Scholar
  65. 65.
    Zelen C, Orgill D, Serena T, Galiano R, Carter M, DiDomenico L, Keller J, Kaufman J, Li W. A prospective, randomised, controlled, multicentre clinical trial examining healing rates, safety and cost to closure of an acellular reticular allogenic human dermis versus standard of care in the treatment of chronic diabetic foot ulcers. Int Wound J. 2017;14(2):307.PubMedCrossRefGoogle Scholar
  66. 66.
    Kirsner RS, Sabolinski ML, Parsons NB, Skornicki M, Marston WA. Comparative effectiveness of a bioengineered living cellular construct vs. a dehydrated human amniotic membrane allograft for the treatment of diabetic foot ulcers in a real world setting. Wound Repair Regen. 2015;23(5):737–44. Scholar
  67. 67.
    Zelen C, Serena T, Gould L, Le L, Carter M, Keller J, Li W. The publication is expected to follow in a future issue of the International Wound Journal. The Early View electronic publication of the study in the International Wound Journal is now available in the Wiley Online Library.
  68. 68.
    Marston WA, Hanft J, Norwood P, Pollak R, Dermagraft Diabetic Foot Ulcer Study Group. The efficacy and safety of dermagraft in improving the healing of chronic diabetic foot ulcers: results of a prospective randomized trial. Diabetes Care. 2003;26:701–5.CrossRefGoogle Scholar
  69. 69.
    Harding K, Sumner M, Cardinal M. A prospective, multicentre, randomised controlled study of human fibroblast-derived dermal substitute (Dermagraft) in patients with venous leg ulcers. Int Wound J. 2013;10:132–7.PubMedCrossRefPubMedCentralGoogle Scholar
  70. 70.
    Hart CE, Loewen-Rodriguez A, Lessem J. Dermagraft: use in the treatment of chronic wounds. Adv Wound Care. 2012;1(3):138–41. Scholar
  71. 71.
    Gabarro P. A new method of grafting. Br Med J. 1943;194(1):723–4.CrossRefGoogle Scholar
  72. 72.
    Reverdin JL. Graffe epidermique. Experience faite dans le service de M. le docteur Guyon, a l’hopital Necker. Bull Imp Soc Chir Paris. 1869;10:511–5.Google Scholar
  73. 73.
    Meek CP. Successful microdermagrafting using the Meek-Wall microdermatome. Am J Surg. 1958;96:557–8.PubMedCrossRefPubMedCentralGoogle Scholar
  74. 74.
    Chih-Chun Y, Tsi-Siang S, Wei-Shia H, Shou-Yen K, Yen-Fei C. Combined use of cutaneous homografts and autografts in extensive burns. Mowlem-Jacksons phenomenon. (transl). J Chir (Paris). 1980;117:443–6.Google Scholar
  75. 75.
    Najarian JS, McCorkle HJ. Experimental grafting of a suspension of skin particles. Surg Forum. 1957;7:125–9.PubMedPubMedCentralGoogle Scholar
  76. 76.
    Xie W, Wang L, Tan H, Wang D, Liu J, Hu B, Huang W, Ren S, Sun K. Microskin grafting by spraying in burn management (transl). Zhonghua Shao Shang Za Zhi. 2002;8:26–8.Google Scholar
  77. 77.
    Gravante G, Di Fede MC, Araco A, Grimaldi M, De Angelis B, Arpino A, Cervelli V, Montone A. A randomized trial comparing ReCell system of epidermal cells delivery versus classic skin grafts for the treatment of deep partial thickness burns. Burns. 2007;33:966–72.PubMedCrossRefGoogle Scholar
  78. 78.
    Yamaguchi Y, et al. Rapid healing of intractable diabetic foot ulcers with exposed bones following a novel therapy of exposing bone marrow cells and then grafting epidermal sheets. Br J Dermatol. 2004;151(5):1019–28.PubMedCrossRefGoogle Scholar
  79. 79.
    Driver VR, Lavery LA, Reyzelman AM, Dutra TG, Dove CR, Kotsis SV, Kim HM, Chung KC. A clinical trial of Integra template for diabetic foot ulcer treatment. Wound Repair Regen. 2015;23(6):891–900. Epub 2015 Oct 19CrossRefPubMedPubMedCentralGoogle Scholar
  80. 80.
    Caravaggi C, Grigoletto F, Scuderi N. Wound bed preparation with a dermal substitute (Hyalomatrix® PA) facilitates re-epithelialization and healing: results of a multicenter, prospective, observational study on complex chronic ulcers (The FAST Study). Wounds. 2011;23(8):228–35.PubMedPubMedCentralGoogle Scholar
  81. 81.
    Alberts B, Johnson A, Lewis J, Raff M, Roberts K, Watson JD. Cell junctions, cell adhesion, and the extracellular matrix. In: Molecular biology of the cell. New York, NY: Garland Science; 2002. p. 1065–125.Google Scholar
  82. 82.
    Lodish H, Berk A, Zipursky SL, Matsudaira P, Baltimore D, Darnell J. Integrating cells into tissues. In: Molecular cell biology. New York, NY: WH Freeman & Co; 2000. p. 968–1002.Google Scholar
  83. 83.
    Pellegrini L, Burke DF, von Delft F, Mulloy B, Blundell TL. Crystal structure of fibroblast growth factor receptor ectodomain bound to ligand and heparin. Nature. 2000;407(6807):1029–34.PubMedCrossRefPubMedCentralGoogle Scholar
  84. 84.
    Kavros SJ, Dutra T, Gonzalez-Cruz R, Liden B, Marcus B, McGuire J, Nazario-Guirau L. The use of PriMatrix, a fetal bovine acellular dermal matrix, in healing chronic diabetic foot ulcers: a prospective multicenter study. Adv Skin Wound Care. 2014;27(8):356–62.PubMedCrossRefPubMedCentralGoogle Scholar
  85. 85.
    Margolis DJ, Allen-Taylor L, Hoffstad O, Berlin JA. Diabetic neuropathic foot ulcers: predicting which ones will not heal. Am J Med. 2003;115:627–31.PubMedCrossRefPubMedCentralGoogle Scholar
  86. 86.
    Lantis J, Magnusson S, Margolis D, Baldursson BT, Kjartansson G, Sigurjonsson G. Cost saving potential of acellular fish skin graft: a cost simulation study on diabetic foot ulcers. 17th Congress of the Asian Society for Vascular Surgery, October 20–23, 2016 Singapore.Google Scholar
  87. 87.
    Randall KL, Booth BA, Miller AJ, Russell CB, Laughlin RT. Use of an acellular regenerative tissue matrix in combination with vacuum-assisted closure therapy for treatment of a diabetic foot wound. J Foot Ankle Surg. 2008;47(5):430–3.PubMedCrossRefGoogle Scholar
  88. 88.
    Albo D, Awad SS, Berger DH, Bellows CF. Decellularized human cadaveric dermis provides a safe alternative for primary inguinal hernia repair in contaminated surgical fields. Am J Surg. 2006;192(5):e12–7.PubMedCrossRefGoogle Scholar
  89. 89.
    Ringley CD, Bochkarev V, Ahmed SI, Vitamvas ML, Oleynikov D. Laparoscopic hiatal hernia repair with human acellular dermal matrix patch: our initial experience. Am J Surg. 2006;192(6):767–72.PubMedCrossRefGoogle Scholar
  90. 90.
    Wilkins R. Acellular dermal graft augmentation in quadriceps tendon rupture repair. Curr Orthop Pract. 2010;21(3):315–9.CrossRefGoogle Scholar
  91. 91.
    Lee DK. A preliminary study on the effects of acellular tissue graft augmentation in acute achilles tendon ruptures. J Foot Ankle Surg. 2008;47(1):8–12.PubMedCrossRefGoogle Scholar
  92. 92.
    Candage R, Jones K, Luchette F, Sinacore JM, Vandevender D, Reed RL 2nd. Use of human acellular dermal matrix for hernia repair: friend or foe? Surgery. 2008;144(4):703–11.PubMedCrossRefGoogle Scholar
  93. 93.
    Mitchell CR, Cima RR. A novel technique for the repair of urostomal hernias using human acellular dermal matrix. Urology. 2011;77(3):746–50.PubMedCrossRefGoogle Scholar
  94. 94.
    Life Cell Corporation. Alloderm defined. Branchburg, NJ: LifeCell Corporation; 2004.Google Scholar
  95. 95.
    Lin HJ, Spoerke N, Deveney C, Martindale R. Reconstruction of complex abdominal wall hernias using acellular human dermal matrix: a single institute experience. Am J Surg. 2009;197(5):599–603. discussion 603PubMedCrossRefPubMedCentralGoogle Scholar
  96. 96.
    Kapfer S, Keshen T. The use of human acellular dermis in the operative management of giant omphalocele. J Pediatr Surg. 2006;41(1):216–20.PubMedCrossRefGoogle Scholar
  97. 97.
    Jamal JE, Kellner DS, Fracchia JA, Armenaka NA. A randomized prospective trial of primary versus AlloDerm closure of buccal mucosal graft harvest site for substitution urethroplasty. Urology. 2010;75(3):695–700.PubMedCrossRefGoogle Scholar
  98. 98.
    Nahabedian MY. AlloDerm performance in the setting of prosthetic breast surgery, infection, and irradiation. Plast Reconstr Surg. 2009;124(6):1743–53.PubMedCrossRefGoogle Scholar
  99. 99.
    Salzberg A. Nonexpansive immediate breast reconstruction using human acellular tissue matrix graft (AlloDerm). Ann Plast Surg. 2006;57(1):1–5.PubMedCrossRefGoogle Scholar
  100. 100.
    Martin B, Sangalang M, Wu S, Armstrong DG. Outcomes of allogenic acellular matrix therapy in treatment of diabetic foot wounds: an initial experience. Int Wound J. 2005;2(2):161–5. US Patents 7,338,757; 6,743,574; 6,734,018. Data on file, LifeNet HealthPubMedCrossRefGoogle Scholar
  101. 101.
    Capito AE, Tholpady SS, Agrawal H, Drake DB, Katz AJ. Evaluation of host tissue integration, revascularization, and cellular infiltration within various dermal substrates. Ann Plast Surg. 2012;68(5):495–500.PubMedCrossRefGoogle Scholar
  102. 102.
    Gottrup F, Apelqvist J, Price P, European Wound Management Association Patient Outcome Group. Outcomes in controlled and comparative studies on non-healing wounds: recommendations to improve the quality of evidence in wound management. J Wound Care. 2010;19(6):237–68.PubMedCrossRefGoogle Scholar
  103. 103.
    Wong I, Burns J, Snyder S. Arthroscopic GraftJacket repair of rotator cuff tears. J Shoulder Elbow Surg. 2010;19(2 Suppl):104–9.PubMedCrossRefGoogle Scholar
  104. 104.
    Snyder SJ, Bond JL. Technique for arthroscopic replacement of severely damaged rotator cuff using “GraftJacket” allograft. Oper Tech Sports Med. 2007;15(2):86–94.CrossRefGoogle Scholar
  105. 105.
    Dopirak R, Bond JL, Snyder SJ. Arthroscopic total rotator cuff replacement with an acellular human dermal allograft matrix. Int J Shoulder Surg. 2007;1(1):7–15.CrossRefGoogle Scholar
  106. 106.
    Winters CL, Brigido SA, Liden BA, et al. A multicenter study involving the use of a human acellular dermal regenerative tissue matrix for the treatment of diabetic lower extremity wounds. Adv Skin Wound Care. 2008;21(8):375–81.PubMedCrossRefGoogle Scholar
  107. 107.
    Gaertner WB, Bonsack ME, Delaney JP. Experimental evaluation of four biologic prostheses for ventral hernia repair. J Gastrointest Surg. 2007;11(10):1275–85.PubMedCrossRefGoogle Scholar
  108. 108.
    Brigido SA. The use of an acellular dermal regenerative tissue matrix in the treatment of lower extremity wounds: a prospective 16-week pilot study. Int Wound J. 2006;3(3):181–7.PubMedCrossRefPubMedCentralGoogle Scholar
  109. 109.
    Reyzelman A, Crews RT, Moore JC, et al. Clinical effectiveness of an acellular dermal regenerative tissue matrix compared to standard wound management in healing diabetic foot ulcers: a prospective, randomized, multicentre study. Int Wound J. 2009;6(3):196–208.PubMedCrossRefPubMedCentralGoogle Scholar
  110. 110.
    Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. Atlanta, GA: U.S. Department of Health and Human Services; 2011.Google Scholar
  111. 111.
    Steinberg JS, Weber B, Kim PJ. Ch. 9: Bioengineered alternative tissues for the surgical management of diabetic foot ulceration. In: Zgonis T, editor. Surgical reconstruction of the diabetic foot and ankle, vol. 2009. Philadelphia, PA: Lippincott Williams and Wilkins; 2009. p. 100–15.Google Scholar
  112. 112.
    Sbitany H, Sandeen SN, Amalfi AN, Davenport MS, Langstein HN. Acellular dermis-assisted prosthetic breast reconstruction versus complete submuscular coverage: a head-to-head comparison of outcomes. Plast Reconstr Surg. 2009;124(6):1735–40.PubMedCrossRefPubMedCentralGoogle Scholar
  113. 113.
    Walters J, Cazzell S, Pham H, Vayser D, Reyzelman A. Healing rates in a multicenter assessment of a sterile, room temperature, acellular dermal matrix versus conventional care wound management and an active comparator in the treatment of full-thickness diabetic foot ulcers. Eplasty. 2016;16:e10. eCollection 2016PubMedPubMedCentralGoogle Scholar
  114. 114.
    Bano F, Barrington JW, Dyer R. Comparison between porcine dermal implant (Permacol) and silicone injection (Macroplastique) for urodynamic stress incontinence. Int Urogynecol J Pelvic Floor Dysfunct. 2005;16:147–50.PubMedCrossRefPubMedCentralGoogle Scholar
  115. 115.
    MacLeod TM, Cambrey A, Williams G, et al. Evaluation of Permacol as a cultured skin equivalent. Burns. 2008;34:1169–75.PubMedCrossRefPubMedCentralGoogle Scholar
  116. 116.
    Hsu PW, Salgado CJ, Kent K, et al. Evaluation of porcine dermal collagen (Permacol) used in abdominal wall reconstruction. J Plast Reconstr Aesthet Surg. 2009;62:1484–9.PubMedCrossRefPubMedCentralGoogle Scholar
  117. 117.
    Saray A. Porcine dermal collagen (Permacol) for facial contour augmentation: preliminary report. Aesthet Plast Surg. 2003;27:368–75.CrossRefGoogle Scholar
  118. 118.
    Zelen CM, Gould L, Serena TE, Carter MJ, Keller J, Li WW. A prospective, randomized, controlled, multi-center comparative effectiveness study of healing using dehydrated human amnion/chorion membrane allograft, bioengineered skin substitute or standard of care for treatment of chronic lower extremity diabetic ulcers. Int Wound J. 2015;12(6):724–32. Scholar
  119. 119.
    Zelen CM, Serena TE, Gould L, Le L, Carter MJ, Keller J, Li WW. Treatment of chronic diabetic lower extremity ulcers with advanced therapies: a prospective, randomized, controlled, multi-center comparative study examining clinical efficacy and cost. Int Wound J. 2016;13(2):272–82. Scholar
  120. 120.
    Lavery LA, Fulmer J, Shebetka KA, Regulski M, Vayser D, Fried D, Kashefsky H, Owings TM, Nadarajah J, Grafix Diabetic Foot Ulcer Study Group. The efficacy and safety of Grafix(®) for the treatment of chronic diabetic foot ulcers: results of a multi-centre, controlled, randomised, blinded, clinical trial. Int Wound J. 2014;11(5):554–60. Epub 2014 Jul 21CrossRefPubMedGoogle Scholar
  121. 121.
    DiDomenico LA, Orgill DP, Galiano RD, Serena TE, Carter MJ, Kaufman JP, Young NJ, Zelen CM. Aseptically processed placental membrane improves healing of diabetic foot ulcerations: prospective, randomized clinical trial. Plast Reconstr Surg Glob Open. 2016;4(10):e1095.PubMedPubMedCentralCrossRefGoogle Scholar
  122. 122.
    Armstrong DG, Attinger CE, et al. Guidelines regarding negative pressure wound therapy (NPWT) in the diabetic foot: results of the Tucson Expert Concensus Conference (TECC) on V.A.C. Therapy Ostomy Wound Manag. 2004;50(4 Suppl B):3s–27s.Google Scholar
  123. 123.
    Blume P, Walters J, Payne W, et al. Comparison of negative pressure wound therapy using vacuum-assisted closure with advanced moist wound therapy in the treatment of diabetic foot ulcers. Diabetes Care. 2008;31(4):641–36.CrossRefGoogle Scholar
  124. 124.
    Driver VR, Blume PA. Evaluation of wound care and health-care use costs in patients with diabetic foot ulcers treated with negative pressure wound therapy versus advanced moist wound therapy. JAPMA. 2014;104(2):147–53.Google Scholar
  125. 125.
    Armstrong D, Lavery L. Negative pressure wound therapy after partial diabetic foot amputation: a multi-centre, randomized controlled trial. Lancet. 2005;366:1704–10.PubMedCrossRefGoogle Scholar
  126. 126.
    Apelqvist J, Armstrong D, Lavery L, et al. Resource utilization and economic costs of care based on a randomized control trial of V.A.C. therapy in the treatment of diabetic foot wounds. Am J Surg. 2008;195(6):782–8.PubMedCrossRefGoogle Scholar
  127. 127.
    Bolton L. Quality randomized clinical trials of topical diabetic foot ulcer healing agents. Adv Wound Care (New Rochelle). 2016;5(3):137–47. Scholar
  128. 128.
    Frykberg RG, Gibbons GW, Walters JL, Wukich DK, Milstein FC. A prospective, multicentre, open-label, single-arm clinical trial for treatment of chronic complex diabetic foot wounds with exposed tendon and/or bone: positive clinical outcomes of viable cryopreserved human placental membrane. Int Wound J. 2016;14:569. [Epub ahead of print].CrossRefPubMedPubMedCentralGoogle Scholar
  129. 129.
    Strauss NH, Brietstein RJ. Fetal bovine dermal repair scaffold used for the treatment of difficult-to-heal complex wounds. Wounds. 2012;24(11):327–34.PubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Division of Vascular and Wound ResearchMount Sinai St. Luke’s Hospital, Icahn School of Medicine at Mount SinaiNew YorkUSA

Personalised recommendations